Chargement en cours...
A patient with metastatic lung adenocarcinoma harboring concurrent EGFR L858R, EGFR germline T790M, and PIK3CA mutations: the challenge of interpreting results of comprehensive mutational testing in lung cancer
Mutational testing has moved to the forefront as an integral component in the management of patients with non-small cell lung cancer (NSCLC). Currently there are three targeted therapies (erlotinib, afatinib, and crizotinib) approved by the Food and Drug Administration (FDA) to treat patients with s...
Enregistré dans:
| Auteurs principaux: | , , |
|---|---|
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
2014
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4151469/ https://ncbi.nlm.nih.gov/pubmed/24453288 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|